Transforming growth factor-β receptor 1: An intervention target for genetic poor cartilage quality induced by

Liang Liu1, Bin Li1, Qingxian Li1

  • 1Department of Orthopedic Surgery, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.

Insights

Prenatal dexamethasone exposure causes inherited poor cartilage quality in offspring, leading to osteoarthritis. Glucosamine treatment reversed these effects by targeting the SP1/TGFβR1 pathway, offering a potential intervention for fetal-originated osteoarthritis.

Area of Science:

  • Biomedical Science
  • Genetics
  • Osteoarthritis Research

Background:

  • Prenatal dexamethasone exposure (PDE) is linked to poor offspring cartilage quality and potential transgenerational genetic effects.
  • Fetal-originated osteoarthritis may stem from inherited poor cartilage quality.

Purpose of the Study:

  • To investigate the molecular mechanisms behind PDE-induced osteoarthritis.
  • To explore the heritability of this condition across generations.
  • To identify early intervention strategies for fetal-originated osteoarthritis.

Main Methods:

  • Rats were exposed to dexamethasone during gestation (F0 generation).
  • Offspring (F1, F2, F3 generations) were bred to assess heritability.
  • F3 generation received glucosamine treatment to evaluate intervention efficacy.
  • Cartilage morphology, function, and molecular markers (SP1, TGFβR1, Smad2, SOX9, ACAN, COL2A1) were analyzed.

Main Results:

  • PDE induced thinner cartilage, reduced chondrocytes, and higher osteoarthritis scores across generations.
  • Expression of SP1, TGFβR1, Smad2, SOX9, ACAN, and COL2A1 was decreased in PDE offspring.
  • Glucosamine treatment reversed these detrimental changes in F3 offspring.
  • Glucosamine upregulated SP1 and TGFβR1 signaling in chondrocytes, promoting matrix synthesis.

Conclusions:

  • PDE causes heritable chondrodysplasia via the SP1/TGFβR1/Smad2/SOX9 pathway, impacting cartilage matrix synthesis.
  • Glucosamine effectively alleviates PDE-induced poor cartilage quality by modulating this pathway.
  • TGFβR1 is identified as a key therapeutic target for fetal-originated osteoarthritis.
Abstract